The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.

Paul M.  Barr

Consulting or Advisory Role - Abbvie; Genentech; Pharmacyclics; Seagen

Research Funding - AstraZeneca (Inst); TG Therapeutics (Inst)

John N.  Allan

Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Epizyme; Genentech; Janssen; Pharmacyclics; TG Therapeutics

Speakers' Bureau - Abbvie; BeiGene; Janssen; Pharmacyclics

Research Funding - BeiGene; Celgene; Genentech; Janssen; TG Therapeutics

Tanya  Siddiqi

Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company

Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene

Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)

William G.  Wierda

Research Funding - Abbvie (Inst); Acerta Pharma (Inst); AstraZeneca (Inst); Cyclacel (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline/Novartis (Inst); Janssen (Inst); Kite, a Gilead Company (Inst); Loxo@Lilly (Inst); Miragen (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics (Inst); Sunesis Pharmaceuticals (Inst); Xencor (Inst)

Constantine Si Lun  Tam

Honoraria - Abbvie; Beigene; Janssen-Cilag; Loxo/Lilly; Novartis; Pharmacyclics; Roche/Genentech

Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche

Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen-Cilag (Inst)

Carolina D.  Moreno

Consulting or Advisory Role - Abbvie; Ascentage Pharma; AstraZeneca; Janssen

Speakers' Bureau - Janssen

Research Funding - Abbvie; Janssen

Alessandra  Tedeschi

Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Janssen (I)

Speakers' Bureau - AbbVie; AstraZeneca; BeiGene; Janssen

Edith  Szafer-Glusman

Employment - Abbvie

Stock and Other Ownership Interests  - Abbvie

Cathy  Zhou

Employment - Abbvie/Pharmacyclics

Stock and Other Ownership Interests  - Abbvie/Pharmacyclics

Chris  Abbazio

Employment - Abbvie

Stock and Other Ownership Interests  - Abbvie; Bristol-Myers Squibb

James P.  Dean

Employment - Abbvie

Stock and Other Ownership Interests  - Abbvie

Anita  Szoke

Employment - Pharmacyclics

Stock and Other Ownership Interests  - Abbvie

Paolo  Ghia

Honoraria - AbbVie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Janssen; Loxo/Lilly; Merck Sharp & Dohme; Roche

Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; Janssen; Loxo/Lilly; Merck Sharp & Dohme; Roche

Research Funding - Abbvie; AstraZeneca; Janssen